Compare TS & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TS | WST |
|---|---|---|
| Founded | 2001 | 1923 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3B | 25.6B |
| IPO Year | 2002 | 2004 |
| Metric | TS | WST |
|---|---|---|
| Price | $53.13 | $353.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $58.80 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 1.5M | 612.7K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.80% | 0.30% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 4.07 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $1.53 | $6.76 |
| Revenue Next Year | $3.59 | $6.22 |
| P/E Ratio | ★ $12.59 | $85.16 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $33.71 | $223.83 |
| 52 Week High | $64.60 | $386.00 |
| Indicator | TS | WST |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 56.32 |
| Support Level | $51.85 | $349.41 |
| Resistance Level | $55.02 | $358.67 |
| Average True Range (ATR) | 1.17 | 6.65 |
| MACD | -0.16 | -0.00 |
| Stochastic Oscillator | 13.40 | 81.23 |
Tenaris SA is engaged in the manufacture and supply of steel pipe products and related services for the energy industry and other industrial applications. The company has one reportable segment, Tubes, which includes the production and sale of steel tubular products such as OCTG, line pipe, and mechanical and structural tubes, mainly for the oil and gas industry. It operates an integrated network of manufacturing, research, and service facilities across the Americas, Europe, the Middle East, Asia, and Africa.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.